XML 32 R20.htm IDEA: XBRL DOCUMENT v3.10.0.1
Stockholders' deficit
9 Months Ended
Sep. 30, 2018
Equity [Abstract]  
Stockholders' deficit
  14. Stockholders’ deficit

 

  a) Common shares

 

On March 29, 2018, the Company issued 165,000 shares of common stock to Leonite Capital, LLC in connection with the closing of a financing of a Senior Secured Convertible Note. The shares were valued at $11,550, or $0.07 per share on the issue date.

 

On April 17, 2018, the Company issued 605,000 shares of common stock to Leonite Capital, LLC in connection with the closing of a financing of a Senior Secured Convertible Note. The shares were valued at $39,450 on the issue date.

 

  b) Warrants

 

In terms of the convertible note agreements entered into with Leonite Capital, LLC, disclosed in note 10 above, the Company agreed to issue warrants exercisable over a total of 15,583,333 shares of common stock at an exercise price of $0.10 per share.

 

In terms of the Series N Convertible debt issued to various accredited investors, disclosed in note 10 above, the Company agreed to issue warrants exercisable over a total of 21,250,000 shares of common stock at an exercise price of $0.12 per share.

 

The fair value of Warrants awarded and revalued during the nine months ended September 30, 2018 were valued at $1,487,729 using the Black Scholes pricing model utilizing the following weighted average assumptions: 

     
    Nine months ended September 30, 2018
     
Calculated stock price    0.06 to 0.08
Risk free interest rate   2.64 to 2.89%
Expected life of warrants (years)    3 to 5 years
expected volatility of underlying stock   198.8 to 203.2%
Expected dividend rate   0%

  

 The movements in warrants is summarized as follows: 

                     
      No. of shares     Exercise price per share     Weighted average exercise price  
                     
Outstanding January 1, 2017       19,637,409        $0.0033 to $.0.03      $ 0.0033  
Granted       29,866,666        $0.03 to $0.10        0.0945  
Exercised                    
Outstanding December 31, 2017       49,504,075       $0.0033 to $.0.03       0.0033  
Granted       36,833,333        $0.10 to $0.12        0.11  
Forfeited/cancelled                    
Exercised                    
Outstanding September 30, 2018       86,337,408       $0.033 to $0.12     $ 0.0870  

 

The following table summarizes information about warrants outstanding at September 30, 2018: 

                                 
        Warrants outstanding       Warrants exercisable  
Exercise price       No. of shares       Weighted average remaining years       Weighted average exercise price       No. of shares       Weighted average exercise price  
                                           
$0.0033       300,000        *                300,000          
$0.03       21,704,075       1.50               21,704,075          
$0.10       43,083,333       4.30               43,083,333          
$0.12       21,250,000       2.70               21,250,000          
                                           
        86,337,408       3.19     $ 0.87       86,337,408     $ 0.87  

 

*       In terms of an agreement entered into with an investor relations company, 300,000 warrants were to be issued as part of the Investor Relations Agreement. These warrants have not been issued as yet, therefore the warrant terms are uncertain.

 

All of the warrants outstanding as of September 30, 2018 are vested. The warrants outstanding as of September 30, 2018 have an intrinsic value of $1,108,205.

 

  c) Stock options

 

Our board of directors adopted the GreeneStone Healthcare Corporation 2013 Stock Option Plan (the “Plan”) to promote our long- term growth and profitability by (i) providing our key directors, officers and employees with incentives to improve stockholder value and contribute to our growth and financial success and (ii) enable us to attract, retain and reward the best available persons for positions of substantial responsibility. A total of 10,000,000 shares of our common stock have been reserved for issuance upon exercise of options granted pursuant to the Plan. The Plan allows us to grant options to our employees, officers and directors and those of our subsidiaries; provided that only our employees and those of our subsidiaries may receive incentive stock options under the Plan. We have granted a total of 480,000 options as of September 30, 2018 under the Plan.

 

No options were issued, exercised or cancelled for the period under review.

 

The following table summarizes information about options outstanding as of September 30, 2018. 

                                 
        Options outstanding       Options exercisable  
Exercise price       No. of shares       Weighted average remaining years       Weighted average exercise price       No. of shares       Weighted average exercise price  
                                           
$0.12       480,000       1.08               480,000          
                                           
        480,000       1.08     $ 0.12       480,000     $ 0.12  

 

As of September 30, 2018, there was no unrecognized compensation costs related to these options and the intrinsic value of the options is $0.